Research Article

Study on the Biological Characteristics of CD133⁺ Cells Interfered by RNA Interference in Gastric Cancer

Ji-wei Yu, Shou-lian Wang, Ju-gang Wu, Rui-qi Lu, Xiao-chun Ni, Cheng Cai, and Bo-jian Jiang

Department of General Surgery, Shanghai 3rd People’s Hospital, School of Medicine, Shanghai Jiao-Tong University, No. 280, Mohe Road, Shanghai 201900, China

Correspondence should be addressed to Bo-jian Jiang; jiang-bj2102@hotmail.com

Received 3 January 2014; Accepted 13 February 2014; Published 19 March 2014

Academic Editors: D. Coppola and M. Ikeguchi

Copyright © 2014 Ji-wei Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. To detect the changes of biological characteristics in gastric cancer cells interfered by CD133-specific small interfering RNA (siRNA). Methods. First to select the siRNA which has the strongest interference effect among 3 siRNAs (i.e., siRNA1, siRNA2, and siRNA3) in KATO-III cells by RT-PCR and Western blotting assays. Then, CD133⁺ cells were sorted out from KATO-III cells using an immunomagnetic bead sorting method and transfected with the selected siRNA. Furthermore, the proliferating characteristics, the antichemotherapeutic assessment, Transwell invasion assay, monoclonal sphere formation assay, and subcutaneous transplanted tumor formation assay in nude mice were investigated.

Results. siRNA3 showed the strongest interference effect in KATO-III cells. As compared to the uninterfered control group, the CD133⁺ cells treated by siRNA3 showed significant decreases in the abilities of proliferation, invasion, clonesphere formation, and resistance to antitumour drugs as well as the weight and size of the transplanted tumor, which was nearly similar to that of CD133⁻ cells. Additionally, the protein expression level of the EMT factor E-cadherin increased while those of EMT-related Snail and N-cadherin decreased in CD133⁺ cells interfered by siRNA3. Conclusion. Inhibition of CD133 gene expression reduces the abilities of gastric cancer cells in proliferation, invasion, clonal sphere formation, and chemoresistance as well as tumor formation in nude mice.

1. Introduction

Gastric cancer (GC) is characterized by high incidences of recurrence and metastasis and low chemosensitivity, whose 5-year survival rate remains less than 24% [1]. Presently, the mechanisms of GC development and progression, invasion and metastasis, and recurrence are not fully understood. In accordance with the hypothesis of tumor-initiating cells (TICs) [2], TICs have the potential of self-renewing, active proliferation, high tumorigenicity, and multidifferentiation; TICs are also the primary cells resistant to radiochemotherapy [3]. Evidence shows that CD133⁺ cells act as TICs in a variety of solid tumors [4–7]. The CD133 expression level in GC tissues is significantly higher than that in the adjacent normal tissues. A higher CD133⁺ expression level is indicative of the deeper infiltration, later TNM stage, more lymph node metastases, and shorter survival time [8–10]. Several studies sorted the CD133⁺ cell subgroup from GC cells and further study of their biological characteristics shows that CD133⁺ cells have significantly higher abilities of proliferation, monoclonal sphere formation, and in vitro tumor formation than CD133⁻ cells [10, 11]. Latest researches have proposed that as a marker for cancer stem cells (CSCs), CD133 expression indicates the poorer prognosis in GC patients and that the indication of CD133⁺ is consistent with the poorer prognosis prediction results of commonly used clinical pathological factors [12, 13]. Therefore, CD133 gene and its products can be a new marker for TICs of GC, or the CD133⁺ cell subgroup contains a relatively high proportion of TICs.

RNA interference (RNAi) is a simple and effective alternative technique of gene knockout. To date, RNAi has widely been used due to the advantages of simplicity, high specificity, and high efficiency [14, 15]. In the present study, RNAi was employed to inhibit CD133 gene expression in GC cells. The changes in CD133⁺ cells before and after RNAi regarding
the CD133 mRNA and protein expression levels, abilities of proliferation, clone sphere formation and in vivo tumor formation, resistance to the chemotherapy drug, and invasion ability as well as invasion-related factors were detected. The results were analyzed to evaluate whether the CD133+ cell subgroup has CSC/TIC-like characteristics.

2. Materials and Methods

2.1. Cell Culture and Immunomagnetic Cell Sorting [10, 11]. KATO-III human GC cells were purchased from the American Type Culture Collection (ATCC, USA) and maintained on a complete Iscove's Modified Dulbecco's Medium (IMDM, ATCC, USA)) containing 20% fetal bovine serum (Hyclone, USA). The cells were subcultured each 4-5 days. The 3rd- to 7th subcultures were harvested and sorted for CD133+ cells using a CD133 immunomagnetic cell sorting kit (Miltenyi, Germany). After sorting, CD133+ cells were cultured in serum-free IMDM at 37°C under 5% CO₂ and saturated humidity.

2.2. Small Interfering RNA (siRNA) Synthesis and Transfection.

Three CD133-specific siRNA fragments were designed and synthesized based on the CD133 gene sequence (Shanghai GenePharma, China). A nonspecific siRNA sequence was designed and synthesized as negative control (Table 1).

Unsorted KATO-III cells were adjusted to 1.5 × 10⁵ cells/mL and then spread on 6-well plates (2 mL/well) in 4 groups (uninterfered group, siRNA1 group, siRNA2 group, and siRNA3 group) overnight. The siRNAs were dissolved in deionized water at 20 μmol/L and then mixed with the IMDM at a ratio of 10 μL: 250 μL per well as the transfection solution a (tube A). The transfection solution b was prepared by mixing Lipofectamine 2000 (Invitrogen, USA) and IMDM at a ratio of 5 μL: 250 μL per well (tube B). After 5 min standing, the mixtures in tubes A and B were pooled and allowed to stand for 20 min. The transfection solutions of siRNA1, siRNA2, and siRNA3 were prepared following the above procedure and then added to the corresponding wells. IMDM (500 μL/well) was added to the uninterfered group as control. After 24 h transfection, the solution was exchanged with serum-containing IMDM for unsorted cell group or serum-free IMDM for CD133+ cell group.

After sorting, CD133+ cells were divided into uninterfered control, nonspecific siRNA control, and siRNA experimental groups (siRNA3 was chosen according to its strongest interference effect as compared with that in group of CD133+ cells) for the following tests.

2.3. Determination of Transfection Efficiency. Unsorted and CD133+ cells were transfected with fluorescence-labeled siRNA3 (FAM-siRNA3). The transfection efficiency was determined by examining cells under an inverted fluorescence microscope (Olympus IX51, Olympus, Japan), that is, the percentage of fluorescence-labeled cells in the total cell population.

2.4. Examination of RNA Interference Effect

2.4.1. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Assay [10, 11]. The cultured cells in different groups were harvested after 48 h transfection and CD133+ cells were applied as a control group at the same time. Total RNA was extracted using the Trizol solution (Invitrogen, USA). The extracted RNA (500 ng) was reverse-transcribed into cDNA using a commercial kit (Takara, Japan). The PCR program was as follows: 42°C for 30 min, 99°C for 5 min, and 5°C for 5 min (10 μL reaction). The cDNA served as a template of PCR amplification using the CD133 upstream primer 5'-TTACGGCACTCTTCACCT-3' and downstream primer 5'-TATTCCACAACGCACGCAA-3' (Shanghai Sangon, China). The product length was 172 bp, and the annealing temperature was 57°C. GAPDH was used as an internal reference of PCR reaction with the upstream primer 5' -ACGGATTTGCTGATGCGGCG-3' and the downstream primer 5' -CTCCTGGAAGATGGATGG-3' (Shanghai Sangon, China). The product length was 197 bp, and the annealing temperature was 55°C. The final products of RT-PCR amplification were checked by agarose gel electrophoresis (Bio-Rad, USA). The results were photographed on a gel imaging system (Bio-Rad, USA) and the relative gray value of each DNA band was estimated. Each measurement was repeated 3 times. The arithmetic mean values of triplicate data were calculated and presented.

2.5. Western Blotting [10, 11]. Unsorted and CD133+ cells were harvested after 72 h transfection and CD133+ cells were used as a control group. And then the harvested cells from differentially transfected group were added with precooled cell lysis buffer. The mixtures were placed on ice for 30 min and then
centrifuged (12000 r/min, 4°C, 5 min). The supernatants were collected for total protein content assay. Fifty micrograms of protein was denaturized, separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and then electrically transferred to a polyvinylidene fluoride film. The specimens were blocked with 5% skim milk for 90 min followed by blocking with the CD133 rabbit anti-human monoclonal antibody (1: 200, Miltenyi, Germany) overnight. Thereafter, the specimens were washed twice with Tris-buffered saline (TBS) with Tween 20 (TBST) three times (10 min each time) and then incubated with horseradish peroxidase-labeled goat anti-rabbit IgG secondary antibody (1:4000, Jackson, USA) at room temperature for 90 min. The specimens were washed twice with agitation using Tris-buffered saline (TBS) with Tween 20 (TBST) and film development. Images were obtained from the films with enhanced chemiluminescence, followed by exposure and film development. Images were obtained from the films and the relative gray values of protein bands on the image were estimated using GelDoc system (Bio-RAD, USA). Each measurement was performed three times. The results were presented as the arithmetic mean values of triplicate data.

2.6. Cell Proliferation Assay [10, 11]. After 24 h transfection, CD133⁺ cells (uninterfered, nonspecific siRNA and siRNA3 group) and CD133⁻ cells were harvested and resuspended in IMDM that contained 20 ng/mL of human epidermal growth factor (EGF) (PeproTech, USA) and 10 ng/mL of basic fibroblast growth factor (bFGF) (PeproTech, USA). The cell suspension was adjusted to 1 × 10⁵ cells/mL and 100 μL aliquots were inoculated to the wells of 96-well plate. Blank control was inoculated with the IMDM. Each group included 5 replicate wells. CCK-8 (10 μL/well, CCK-8 kit purchased from Cayman, USA) was added after 24, 48, and 72 h transfection. The optical density of cell suspension in each well was determined at 450 nm (OD₄₅₀) using an enzyme-linked immunosorbent analyzer (Bio-Rad 680, Bio-Rad, USA). Results were presented as the mean values of replicate measurements and the cell proliferation rate was compared among different groups. Cell growth inhibition rate (%) = (1 – OD₄₅₀ of the transfected cell group/OD₄₅₀ of the blank cell group) × 100%.

2.7. Cell Invasion Assay. Aliquots (100 μL) of diluted Matrigel (BD, USA) were added to the polycarbonate membrane in the upper chamber of Transwell chamber (Coring, USA). After the Matrigel polymerized, 100 μL of cell suspension (1 × 10⁵ cells/mL) was added to the upper chamber, and 500 μL of IMDM containing 20% fetal bovine serum was added to the lower chamber. The Transwell chamber was placed in a 37°C incubator. After 24 h incubation, the Transwell chamber was taken out and washed twice with PBS. The cells adhesive to the chamber surface were fixed with 5% glutaraldehyde and stained with crystal violet (Beyotime, China), followed by PBS washing twice. Cells adhesive to the upper chamber surface were wiped off using a cotton swab and those adhesive to the lower chamber surface were examined by microscopy.

2.8. Western Blotting of the Changes in Epithelial-Mesenchymal Transition (EMT)-Related Protein Expression. After 72 h transfection, CD133⁺ cells (uninterfered, non-specific siRNA and siRNA3 group) and CD133⁻ cells as a control group were harvested. Total protein components were extracted and the changes in Snail (mouse anti-human Snail monoclonal antibody, CST, USA), N-cadherin (mouse anti-human N-cadherin monoclonal antibody, CST, USA), and E-cadherin (mouse anti-human E-cadherin monoclonal antibody, CST, USA) protein expression were detected by Western blotting following the same procedure of CD133 protein assay.

2.9. Monoclonal Formation Assay [10, 11]. After 24 h transfection, CD133⁺ cells (uninterfered, non-specific siRNA and siRNA3 group) and CD133⁻ cells as a control group were harvested and then diluted to 1 × 10⁵ cells/mL by limiting dilution. Ten microliter of the diluted cell suspension was inoculated to each well of the 96-well plate, followed by addition of 190 μL of the IMDM containing 20 ng/mL of EGF and 10 ng/mL of bFGF. Each group included 48 wells. After 3–4 weeks, the clonal sphere formation of cell cultures was examined and compared among different groups.

2.10. Chemotherapy Drug Susceptibility Testing [10, 11]. After 48 h transfection, CD133⁺ cells (uninterfered, non-specific siRNA and siRNA3 group) and CD133⁻ cells were harvested. Then, the cell suspensions were diluted to 1 × 10⁵ cells/mL with IMDM containing 10 mM 5-Fu (Sigma, USA). Aliquots (10 μL) of the cell suspension were inoculated to the corresponding wells of the 96-well plate. Blank control was prepared with cells of the uninterfered group without 5-Fu treatment. Each group included 5 replicate wells. The cell cultures were incubated at 37°C under 5% CO₂ and saturated humidity for 72 h. The cell growth ability was examined using a CCK-8 kit (Cayman, USA). Cell growth inhibition rate (%) = [1 – OD values₅₅₀(5-Fu)/OD values₅₅₀] × 100%.

2.11. Subcutaneous Tumor Formation in Nude Mice [10, 11]. A GC animal model was established in twelve 4–6-week-old nude mice (body weight 15–20 g, BALB/c nu/nu, Shanghai SIPPR-BK Laboratory Animal Ltd, China). The animals were fed in a non-special pathogen-class breeding room at the temperature of 22–25°C under the humidity of (50 ± 5)% and a light cycle of 12 h. The animals were supplied with conventional feeds and water.

After 24 h transfection, CD133⁺ cells of the uninterfered control, non-specific siRNA control, and siRNA3 experimental groups after 24 h transfection and CD133⁻ cells were harvested and resuspended in PBS. The cell suspensions were then inoculated subcutaneously to the left side of armpits in the mice (1 × 10⁶ cells/mouse). Each animal group included 4 animals. The formation rate and formation time of the subcutaneously transplanted tumor were examined and recorded. After 4 weeks, the mice were sacrificed by craning the neck. The subcutaneously transplanted tumors were taken for determination of the volume and weight. The present animal experiment was reviewed and approved by
the Hospital Ethics Committee and Animal Management Committee.

2.12. Immunohistochemical Staining (IHS). Tissue specimens of the transplanted tumor were fixed in 10% formalin and embedded in paraffin, followed by immunohistochemical (IHC) staining using the Strept avidin-biotin complex (SABC) method. All specimens were cut into 4 μm-thick serial sections and then incubated with the rabbit anti-human CD133 monoclonal antibody (Miltenyi, Germany) at 4°C overnight followed by the biotinylated secondary antibody (goat anti-rabbit IgG, Jackson, USA) at room temperature for 30 min. Thereafter, the sections were incubated with SABC reagent (Santa Cruz, USA) at room temperature for 30 min and then stained with 3,3-diaminobenzidine. After rinsed with distilled water, the sections were counterstained with hematoxylin. Finally, the sections were dehydrated, transparentized, and mounted, then examined by microscopy. The staining of hematoxylin eosin (HE) was applied as regular microscopic observations.

2.13. Statistical Analyses. Data analyses were performed in SPSS 13.0 (IL, USA). The experimental results were expressed as mean ± standard deviation. Comparisons between different groups were performed using one-way analysis of variance. P < 0.05 was considered statistically significant.

3. Results

3.1. Transfection Efficiency. After 24 h transfection with FAM-siRNA3, the majority of unsorted and sorted CD133⁺ KATO-III cells showed green fluorescent and the corresponding transfection efficiencies were (72.3 ± 6.5)% and (87.7 ± 8.1)%, respectively (Figure 1).

3.2. Comparison of the Interference Effects of Different siRNA Fragments on Unsorted Cells. Results of the RT-PCR assay showed that the relative gray value indicative of CD133 mRNA expression level in GC cells was significantly lower in the siRNA3 experimental group (0.578 ± 0.135) than in the uninterfered control group (0.896 ± 0.135; P = 0.045) (Figures 2(a) and 2(b)). Results of Western blotting confirmed that the relative gray value of CD133 protein expression in GC cells was significantly lower in the siRNA3 experimental group (0.587 ± 0.137) than in the uninterfered control group (0.931 ± 0.140; P = 0.038) (Figures 2(c) and 2(d)). Therefore, siRNA3 was chosen and used for the following tests due to the most obvious decreases in the levels of mRNA and protein of CD133 in siRNA3 group in comparison with that in siRNA1 group or in siRNA2 group.

3.3. The Interference Effect of siRNA3 on CD133⁺ Cells. Results of the RT-PCR assay showed that the CD133 mRNA expression level of CD133⁺ cells significantly decreased in
3.4. In Vitro Proliferation Activity. Results of the CCK-8 assay showed that, after 24 h, 48 h, and 72 h transfection, the cell proliferation activity of CD133+ cells in the siRNA3 experimental group (0.073 ± 0.014, 0.091 ± 0.016, and 0.133 ± 0.018, resp.) decreased by (31.1 ± 1.3)%,(43.8 ± 1.6)%and(52.6 ± 1.8)%asrespectivelycomparedtolostrs of the uninterfered control group (0.106 ± 0.007, P = 0.018; 0.162 ± 0.006, P = 0.002; and 0.280 ± 0.009, P < 0.001), but no significant differences occurred between siRNA3 group and CD133− cells group at 24 h, 48 h and 72 h comparison (Figure 4).

3.5. Monoclonal Formation Ability. After incubated in EGF- and bFGF-containing serum-free IMDM medium for 4 weeks, the number of clonal sphere formations by CD133+ cells was significantly lower in the siRNA3 experimental group (11.6 ± 1.9) than that in the uninterfered (22.6 ± 3.0; P = 0.007) and non-specific siRNA control groups (21.6 ± 3.0; P = 0.009), but no clonal sphere formation could be identified in CD133− cells group (Figure 5).

3.6. Chemotherapy Drug Susceptibility. Results of the CCK-8 assay showed that after 5-Fu treatment for 72 h, the cell growth inhibition rate was significantly higher in the siRNA3 experimental group (62.4 ± 3.3)% than that in the uninterfered (18.6 ± 1.8)% (P < 0.001) and non-specific siRNA control groups (21.5 ± 2.2)% (P < 0.001), but no significant difference occurred between the siRNA3 group and CD133− cells group (Figure 6).

3.7. In Vivo Tumor Formation Ability in Nude Mice. Four weeks after subcutaneous inoculation of GC cell, the formation rate of transplanted tumor was 100% (4/4) in the siRNA3 group as well as the uninterfered and non-specific siRNA control groups but no formation of transplanted tumor by
Figure 3: Electrophoresis bands and levels of CD133 mRNA and protein in CD133+ cells group (uninterfered, nonspecific siRNA and siRNA3) and CD133− cells group. (a) Electrophoresis bands of CD133 mRNA in Group 1 (uninterfered), 2 (interfered with nonspecific siRNA), 3 (interfered with siRNA3), and 4 (CD133− cells). GAPDH was used as control. (b) The semiquantitative levels of CD133 mRNA were calculated. (c) Electrophoresis bands of CD133 protein in Group 1, 2, 3, and 4. GAPDH was used as control. (d) The semiquantitative levels of CD133 protein were calculated.

Figure 4: The proliferation ability of CD133+ cells groups (uninterfered, nonspecific siRNA and siRNA3) and CD133− cells group. At 24, 48, and 72 h following transfection, the absorbance values of cell suspensions in the uninterfered control, nonspecific siRNA control, and siRNA3 experimental groups were shown.

Using CD133− cells in CD133− cells group (0/4). The sizes of the transplanted tumor were (206.7 ± 30.6) mm3 in the siRNA3 experimental group and (313.3 ± 41.6) mm3, (340.0 ± 60.0) mm3 in the uninterfered and non-specific siRNA control groups, respectively. The weights of the transplanted tumor were (132.3 ± 21.6) mg in the siRNA3 experimental group and (200.5 ± 26.6) mg and (217.6 ± 38.4) mg in the uninterfered and non-specific siRNA control groups, respectively. Comparison analysis showed that the volume and the weight of the transplanted tumor in the siRNA3 experimental group were both significantly less than that in the uninterfered control group (P = 0.023 and P = 0.026, resp.) (Figures 7(a) and 7(b)).

HE staining showed that the transplanted tumor tissues contained less mesenchyme and more parenchyma. The GC cells were arranged in a cord-like structure, with scattered necrosis. The large GC cells contained abundant cytoplasm with large nucleus and evident pleomorphic characteristics (Figure 7(c)). IHC staining showed that CD133 expression particles were located in the cell membrane and cytoplasm (Figure 7(d)), which was similar to the profiles in pathology and immunopathology in human samples of GC.

3.8. Cell Invasion Ability

3.8.1. Transwell Chamber Assay. Results of the Transwell chamber assay showed that the number of invasive cells
adhered on the lower chamber surface was significantly less in the siRNA3 experimental group (41.7 ± 6.0) than in the uninterfered (131.7 ± 10.5, P < 0.001) and nonspecific siRNA-interfered control groups (130.3 ± 11.0, P < 0.001) but significantly higher than that in CD133− cells group (21.7 ± 4.5, P = 0.010) (Figure 8).

3.8.2. Protein Expression of EMT-Related Factors. Results of Western blotting showed that the protein expression levels of Snail (0.283 ± 0.024) and N-cadherin (0.622 ± 0.052) in the siRNA3 group significantly decreased as compared to those of the uninterfered (0.839 ± 0.064, P < 0.001; 0.914 ± 0.033, P = 0.001, resp.) and nonspecific siRNA control groups (0.878 ± 0.052, P < 0.001; 0.870 ± 0.066, P = 0.007, resp.). In contrast, the E-cadherin protein expression level significantly increased in the siRNA3 experimental group (0.763 ± 0.030) compared to those of the uninterfered (0.559 ± 0.029, P = 0.004) and nonspecific siRNA-interfered control groups (0.542 ± 0.056, P = 0.001). However, protein expressions of Snail and E-cadherin in siRNA3 group were not significantly higher than that in CD133− cells group, but N-cadherin protein expression in siRNA3 group was significantly higher than that in CD133− cells group (P = 0.023) (Figure 9).

4. Discussion

The key to success of RNAi lies in the sequence structure of siRNA. For improving the silencing effect of siRNA, one should focus on the following principles in siRNA designing [16]. (1) Start at 50–100 nt downstream of the start codon, avoid UTRs at the 5′ or 3′ end, and search for the sequence of AA (N19). (2) Choose G or C at the 1 nt and A or U at the 19 nt of the sense strand and ensure the energy higher at the 5′ end than at the 3′ end of the double-strand. (3) Phosphorylate the 5′ end and have 2 dTdT or UU overhanging at the 3′ end. (4) Avoid the presence of consecutive G or C and have the optimal GC content of 30%–52%. In accordance with the above principles, 3 CD133-specific siRNA fragments were designed and synthesized in the present study. These siRNA fragments were separately transfected into unsorted KATO-III cells using Lipofectamine 2000. Subsequent detection of the changes in the CD133 mRNA and protein levels before and after transfection demonstrated that siRNA3 posed the
most significant inhibitory effect on the GC cells as compared to the other 2 fragments. Additionally, FAM-siRNA3 transfection test demonstrated that the transfection efficiency was up to \((72.3 \pm 6.5)\%\). This result indirectly proved that the transfection technique and inhibition efficiency were reliable. Therefore, siRNA3 was chosen for further transfection tests in an attempt to examine the changes in the biological characteristics of CD133+ cells after RNAi.

As compared to CD133− cells, CD133+ KATO-III cells have better proliferation ability [8]. In the present study, the inhibition of CD133 gene expression in CD133+ KATO-III GC cells resulted in significant decreases in the cell proliferation activity, in which proliferating ability almost decreased to that of CD133− cells of GC. This observation proved that CD133 is associated with cell proliferation, which is consistent with previous finding regarding the positive correlation between CD133 gene expression and colon cancer cell proliferation [17].

CD133 expression can enhance the motility of cells and thus promote the invasion and distant metastasis of cancer cells [18]. In the present study, the experimental data confirmed that inhibition of CD133 gene expression led to significant reduction of the cell invasion ability, which was nearly similar to the invasion ability of CD133− cells of GC. EMT can induce mesenchymal-like changes in epithelial cells, thereby promoting tumor invasion and metastasis [19].

A variety of highly malignant tumors are associated with EMT in the invasion and metastasis processes [20, 21]. Results of the present study showed that, after the inhibition of CD133 gene expression in GC cells, Snail and N-cadherin protein expression was downregulated while E-cadherin protein expression was upregulated. These suggest that CD133...
Figure 8: Effects of siRNA3 interference on the invasion ability of CD133⁺ cells groups (uninterfered, nonspecific siRNA and siRNA3) and CD133⁻ cells group. (a) Positive particles with violet could be identified on the cells infiltrated through chamber filter and attached on the lower side of filter (×100 magnification). (b) The average number of cells infiltrated through the filter.

Figure 9: Expressions of Snail, N-cadherin, and E-cadherin proteins in CD133⁺ cells groups (uninterfered, nonspecific siRNA and siRNA3) and CD133⁻ cells group. (a) Electrophoresis bands. GAPDH was used as control. (b) Semiquantitative levels of EMT-related protein expression.
potentially promotes GC cell invasion and metastasis by accelerating the process of EMT.

Our previous studies have shown the clonal sphere formation ability of CD133+ GC cells is significantly higher than that of CD133− cells [10]. In the present study, we further proved that, after CD133 gene expression was inhibited by RNAi in CD133+ KATO-III cells, the clonal sphere formation rate and size significantly decreased as compared to those of the control groups. A study of colon cancer demonstrated that the clonal sphere formation ability of CD133+ colon cancer cells is significantly higher than that of CD133− cells [18]. Together, the above findings indicate that CD133− cells have high clonal forming ability. After CD133 gene expression was inhibited, the size and weight of the subcutaneous transplanted tumor in nude mice significantly decreased as compared to those of the una interference control groups. This was despite a lack of significant differences in the tumor formation rate between the siRNA3 experimental and una interference control groups, possibly due to the short-term effect of siRNA interference using Lipofectamine 2000 for transfection. A previous study of colorectal cancer has proven that CD133+ cells have relatively high in vivo tumor formation ability [22, 23]. CD133+ GC cells have been considered to be the primary cells resistant to anticancer drugs [4]. CD133 plays a role in drug resistance by regulating the expression of antiapoptotic protein and inhibitor of apoptosis protein of Bcrp1 and the MGMT [24]. Our previous study has shown that, as compared to CD133− cells, CD133+ cells are not sensitive to chemotherapeutic agents such as 5-Fu [10]. In the present study, we proved that inhibition of CD133 gene expression led to significant increases in the sensitivity of CD133+ GC cells to 5-Fu.

5. Conclusions

After RNAi inhibition of CD133 gene expression, CD133+ KATO-III GC cells showed significantly decreases in the CD133 mRNA and protein expression levels, cell proliferation activity, and abilities of invasion, clonal sphere formation, and in vivo tumor formation, with enhanced sensitivity to chemotherapeutic drug. The reduction of cancer cell invasion ability after RNAi inhibition may be achieved promoting the process of EMT. Therefore, research of CD133 gene and its products may provide new targets for diagnosis and treatment of GC.

Conflict of Interests

All authors declared that they had no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Ji-wei Yu contributed in study design, definition of intellectual content, and literature research and Shou-lian Wang contributed in literature research, experimental studies, data acquisition, data analysis, statistical analysis, and paper preparation. This experiment was also assisted by Ju-gang Wu in IHC staining, Cheng Cai in Transwell study, Rui-qi Lu in biological evaluations, and Xiao-chun Ni in data acquisition and data analysis. Bo-jiang Jiang contributed as a guarantor of the integrity of the entire study, study concepts, study design, and paper review. Ji-wei Yu and Shou-lian Wang contributed equally to this study and Bo-jiang Jiang was the corresponding author of this paper.

Acknowledgments

This study was supported by the National Science Foundation (81101850), the Shanghai Municipal Health Bureau Foundation of China (2000018), the Shanghai Municipal Education Commission Fund (jdy10022), and the Research Fund of the Medicine School of Shanghai Jiao-tong University (YZ1055). Drs XQ Li and GY Du greatly appreciated for their support for microscopic observations of pathological study. Ji-wei Yu and Shou-lian Wang are first coauthors.

References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, ”Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] T. Rey S, J. Morrison, M. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001.
[3] A. Schulenburg, K. Brämwig, H. Herrmann et al., ”Neoplastic stem cells: current concepts and clinical perspectives,” Critical Reviews in Oncology/Hematology, vol. 76, no. 2, pp. 79–98, 2010.
[4] M. Olempska, P. A. Eisenach, O. Ammerpohl, H. Ungeforen, F. Fandrich, and H. Kalthoff, ”Detection of tumor stem cell markers in pancreatic carcinoma cell lines,” Hepatobiliary and Pancreatic Diseases International, vol. 6, no. 1, pp. 92–97, 2007.
[5] S. Ma, W. C. Kwok, T. K.-W. Lee et al., ”Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations,” Molecular Cancer Research, vol. 6, no. 7, pp. 1146–1153, 2008.
[6] L. Zhu, P. Gibson, D. S. Currie et al., ”Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation,” Nature, vol. 457, no. 7229, pp. 630–637, 2009.
[7] G. J. Klarmann, E. M. Hurt, L. A. Mathews et al., ”Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature,” Clinical and Experimental Metastasis, vol. 26, no. 5, pp. 433–446, 2009.
[8] J.-W. Yu, P. Zhang, J.-G. Wu et al., ”Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocarcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 141, 2010.
[9] P. Zhao, Y. Li, and Y. Lu, ”Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma,” BMC Cancer, vol. 10, article 218, 2010.
[10] R. Q. Lu, J. G. Wu, G. C. Zhou, H. G. Jiang, J. W. Yu, and B. J. Jiang, ”Sorting of CD133+ subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties,” Zhonghua Wei Chang Wai Ke Za Zhi, vol. 15, no. 2, pp. 174–179, 2012.
[11] S. Takaishi, T. Okumura, S. Tu et al., ”Identification of gastric cancer stem cells using the cell surface marker CD44,” Stem Cells, vol. 27, no. 5, pp. 1006–1020, 2009.
[12] L. Wen, X. Z. Chen, K. Yang et al., “Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review,” *PLoS ONE*, vol. 8, no. 3, Article ID e59154, 2013.

[13] Y. Wakamatsu, N. Sakamoto, H. Z. Oo et al., “Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer,” *Pathology International*, vol. 62, no. 2, pp. 112–119, 2012.

[14] A. de Fougerolles, H.-P. Vornlocher, J. Maraganore, and J. Lieberman, “Interfering with disease: a progress report on siRNA-based therapeutics,” *Nature Reviews Drug Discovery*, vol. 6, no. 6, pp. 443–453, 2007.

[15] M. Stevenson, “Mechanisms of disease: therapeutic potential of RNA interference,” *The New England Journal of Medicine*, vol. 351, no. 17, pp. 1772–1777, 2004.

[16] D.-H. Xu, C. Huang, L.-Y. Liu, and T.-S. Song, “New progress of the highly efficient siRNA design,” *Yi Chuan*, vol. 28, no. 11, pp. 1457–1461, 2006.

[17] D. D. Fang, Y. J. Kim, C. N. Lee et al., “Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery,” *British Journal of Cancer*, vol. 102, no. 8, pp. 1265–1275, 2010.

[18] T. M. A. Elsaba, L. Martinez-Pomares, A. R. Robins et al., “The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer,” *PLoS ONE*, vol. 5, no. 5, Article ID e10714, 2010.

[19] M. A. Nieto, “The ins and outs of the epithelial to mesenchymal transition in health and disease,” *Annual Review of Cell and Developmental Biology*, vol. 27, pp. 347–376, 2011.

[20] R. Kalluri, “EMT: when epithelial cells decide to become mesenchymal-like cells,” *The Journal of Clinical Investigation*, vol. 119, no. 6, pp. 1417–1419, 2009.

[21] E. W. Thompson, D. F. Newgreen, and D. Tarin, “Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?” *Cancer Research*, vol. 65, no. 14, pp. 5991–5995, 2005.

[22] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” *Nature*, vol. 445, no. 7123, pp. 106–110, 2007.

[23] L. Ricci-Vitiani, D. G. Lombardi, E. PiloZZi et al., “Identification and expansion of human colon-cancer-initiating cells,” *Nature*, vol. 445, no. 7123, pp. 111–115, 2007.

[24] G. Liu, X. Yuan, Z. Zeng et al., “Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma,” *Molecular Cancer*, vol. 5, article 67, 2006.